Published:
European Centre for Disease Control and Prevention (ECDC), 2021
Published in:
Eurosurveillance, 26 (2021) 31
Language:
English
DOI:
10.2807/1560-7917.es.2021.26.31.2100616
ISSN:
1560-7917
Origination:
Footnote:
Description:
We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.